logo

KREBSBIO vs WINDLAS: Stock Comparison

KREBS BIOCHEMICALS & IND vs WINDLAS BIOTECHUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

WINDLAS BIOTECH is the larger company by market capitalisation. KREBS BIOCHEMICALS & IND shows a lower P/E, while WINDLAS BIOTECH shows a higher dividend yield, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

KREBSBIO leads 3; WINDLAS leads 6 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

KREBSBIOWINDLAS

Valuation lens

What price are you paying?

Market CapContext only
₹125 Cr
₹1,851 Cr
P/E RatioKREBSBIO has the lower reading
0x ✓
38.76x
P/B RatioKREBSBIO has the lower reading
0x ✓
3.26x
EPSWINDLAS has the higher reading
₹-1.15
₹7.58 ✓
Book ValueContext only
—
₹275.2
Dividend YieldWINDLAS has the higher reading
0%
0.71% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
WINDLAS is the larger company
₹1,851 Cr vs ₹125 Cr
P/E Ratio
KREBSBIO has a lower P/E
0x vs 38.76x
P/B Ratio
KREBSBIO has a lower P/B
0x vs 3.26x
EPS
WINDLAS has higher earnings per share
₹7.58 vs ₹-1.15
Dividend Yield
WINDLAS has a higher dividend yield
0.71% vs 0%
Revenue Growth (TTM YoY)
WINDLAS has faster revenue growth
17.7% vs 11.6%
EPS Growth (TTM YoY)
KREBSBIO has faster EPS growth
0% vs -2.6%
ROCE
WINDLAS has a higher ROCE
11.95% vs -15.89%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKREBSBIOWINDLAS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKREBSBIOWINDLAS
Live Price₹57.48₹900.4
Day Change2.53%2.17%
Volume3,57048,867
52-Week High₹76.85₹1,181.9
52-Week Low₹38.33₹697.4
Distance from 52W High-25.2%-23.82%

Valuation

MetricKREBSBIOWINDLAS
Market Cap₹125 Cr₹1,851 Cr
P/E Ratio0x38.76x
P/B Ratio0x3.26x
EPS₹-1.15₹7.58
Book Value—₹275.2
Dividend Yield0%0.71%

Growth

MetricKREBSBIOWINDLAS
Revenue Growth (TTM YoY)11.6%17.7%
EPS Growth (TTM YoY)0%-2.6%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricKREBSBIOWINDLAS
ROE—11.44%
ROCE-15.89%11.95%
Net Margin-71.35%7.35%
Operating Margin-41.49%10.15%
Debt to Equity—0.05x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricKREBSBIOWINDLAS
Promoter Holding72.74%63.31%
FII Holding0.5%2.08%▲ 0.04 pp
DII Holding0%7.24%▼ 2.6 pp
Public Holding26.76%27.36%▲ 2.56 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KREBS BIOCHEMICALS & IND and WINDLAS BIOTECH.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.